» Articles » PMID: 33330414

Tailored Cytokine Optimization for Culture Platforms Targeting the Expansion of Human Hematopoietic Stem/Progenitor Cells

Overview
Date 2020 Dec 17
PMID 33330414
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Umbilical cord blood (UCB) has been established as an alternative source for hematopoietic stem/progenitor cells (HSPC) for cell and gene therapies. Limited cell yields of UCB units have been tackled with the development of cytokine-based expansion platforms. To improve the effectiveness of these platforms, namely targeting clinical approval, in this study, we optimized the cytokine cocktails in two clinically relevant expansion platforms for HSPC, a liquid suspension culture system (CS_HSPC) and a co-culture system with bone marrow derived mesenchymal stromal cells (BM MSC) (CS_HSPC/MSC). Using a methodology based on experimental design, three different cytokines [stem cell factor (SCF), fms-like tyrosine kinase 3 ligand (Flt-3L), and thrombopoietin (TPO)] were studied in both systems during a 7-day culture under serum-free conditions. Proliferation and colony-forming unit assays, as well as immunophenotypic analysis were performed. Five experimental outputs [fold increase (FI) of total nucleated cells (FI TNC), FI of CD34 cells, FI of erythroid burst-forming unit (BFU-E), FI of colony-forming unit granulocyte-monocyte (CFU-GM), and FI of multilineage colony-forming unit (CFU-Mix)] were followed as target outputs of the optimization model. The novel optimized cocktails determined herein comprised concentrations of 64, 61, and 80 ng/mL (CS_HSPC) and 90, 82, and 77 ng/mL (CS_HSPC/MSC) for SCF, Flt-3L, and TPO, respectively. After cytokine optimization, CS_HSPC and CS_HSPC/MSC were directly compared as platforms. CS_HSPC/MSC outperformed the feeder-free system in 6 of 8 tested experimental measures, displaying superior capability toward increasing the number of hematopoietic cells while maintaining the expression of HSPC markers (i.e., CD34 and CD34CD90) and multilineage differentiation potential. A tailored approach toward optimization has made it possible to individually maximize cytokine contribution in both studied platforms. Consequently, cocktail optimization has successfully led to an increase in the expansion platform performance, while allowing a rational side-by-side comparison among different platforms and enhancing our knowledge on the impact of cytokine supplementation on the HSPC expansion process.

Citing Articles

Advances in ex vivo expansion of hematopoietic stem and progenitor cells for clinical applications.

Branco A, Rayabaram J, Miranda C, Fernandes-Platzgummer A, Fernandes T, Sajja S Front Bioeng Biotechnol. 2024; 12:1380950.

PMID: 38846805 PMC: 11153805. DOI: 10.3389/fbioe.2024.1380950.


Effects of different concentrations of nicotinamide on hematopoietic stem cells cultured .

Ren Y, Cui Y, Wang H World J Stem Cells. 2024; 16(2):163-175.

PMID: 38455103 PMC: 10915957. DOI: 10.4252/wjsc.v16.i2.163.


Apoptosis in megakaryocytes: Safeguard and threat for thrombopoiesis.

Yang S, Wang L, Wu Y, Wu A, Huang F, Tang X Front Immunol. 2023; 13:1025945.

PMID: 36685543 PMC: 9845629. DOI: 10.3389/fimmu.2022.1025945.


Hypothermic Preservation of Adipose-Derived Mesenchymal Stromal Cells as a Viable Solution for the Storage and Distribution of Cell Therapy Products.

Branco A, Tiago A, Laranjeira P, Carreira M, Milhano J, Dos Santos F Bioengineering (Basel). 2022; 9(12).

PMID: 36551011 PMC: 9774331. DOI: 10.3390/bioengineering9120805.


Living Biomaterials to Engineer Hematopoietic Stem Cell Niches.

Petaroudi M, Rodrigo-Navarro A, Dobre O, Dalby M, Salmeron-Sanchez M Adv Healthc Mater. 2022; 11(20):e2200964.

PMID: 35933595 PMC: 11469072. DOI: 10.1002/adhm.202200964.


References
1.
Naldini L . Gene therapy returns to centre stage. Nature. 2015; 526(7573):351-60. DOI: 10.1038/nature15818. View

2.
Frias A, Porada C, Crapnell K, Cabral J, Zanjani E, Almeida-Porada G . Generation of functional natural killer and dendritic cells in a human stromal-based serum-free culture system designed for cord blood expansion. Exp Hematol. 2007; 36(1):61-8. PMC: 2214851. DOI: 10.1016/j.exphem.2007.08.031. View

3.
Csaszar E, Cohen S, Zandstra P . Blood stem cell products: toward sustainable benchmarks for clinical translation. Bioessays. 2013; 35(3):201-10. DOI: 10.1002/bies.201200118. View

4.
Ohmizono Y, SAKABE H, Kimura T, Tanimukai S, Matsumura T, Miyazaki H . Thrombopoietin augments ex vivo expansion of human cord blood-derived hematopoietic progenitors in combination with stem cell factor and flt3 ligand. Leukemia. 1997; 11(4):524-30. DOI: 10.1038/sj.leu.2400588. View

5.
Zandstra P, Conneally E, Petzer A, Piret J, Eaves C . Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc Natl Acad Sci U S A. 1997; 94(9):4698-703. PMC: 20787. DOI: 10.1073/pnas.94.9.4698. View